Skip to main content
Top
Published in: International Cancer Conference Journal 1/2017

01-01-2017 | Case report

Exacerbation of gemcitabine-related pneumonia during radiotherapy for extrapulmonary lesion

Author: Yukihiro Hama

Published in: International Cancer Conference Journal | Issue 1/2017

Login to get access

Abstract

Late-onset gemcitabine pulmonary toxicity is rare and association between pulmonary toxicity and radiotherapy to the extrapulmonary sites is controversial. Here, we report a case of acute exacerbated fatal interstitial pneumonia during radiotherapy to the extrapulmonary site. A 73-year-old woman with pelvic lymph node metastases from urothelial carcinoma underwent palliative radiotherapy after failure of gemcitabine-containing and gemcitabine-non-containing chemotherapy. Gemcitabine-containing chemotherapy had finished 13 months prior to the radiotherapy due to grade 3 pulmonary toxicity. During the course of radiotherapy to the pelvic lesion, she was complicated with fatal acute interstitial pneumonia even though the lung tissue was not irradiated. To the best of our knowledge, this is the first reported case of fatal gemcitabine-related pulmonary toxicity during radiotherapy for extrapulmonary lesion. Although the association between late-onset pulmonary toxicity and radiotherapy is controversial, caution should be paid to a patient with a history of gemcitabine-related pulmonary toxicity who will undergo radiotherapy even though the lung volume is not irradiated.
Literature
1.
go back to reference Arrieta O, Gallardo-Rincon D, Villarreal-Garza C et al (2009) High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 4:845–852CrossRefPubMed Arrieta O, Gallardo-Rincon D, Villarreal-Garza C et al (2009) High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 4:845–852CrossRefPubMed
3.
go back to reference Maas KW, van der Lee I, Bolt K et al (2003) Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 41:345–351CrossRefPubMed Maas KW, van der Lee I, Bolt K et al (2003) Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 41:345–351CrossRefPubMed
4.
go back to reference Dimopoulou I, Efstathiou E, Samakovli A et al (2004) A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 15:1250–1255CrossRefPubMed Dimopoulou I, Efstathiou E, Samakovli A et al (2004) A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 15:1250–1255CrossRefPubMed
5.
go back to reference Belknap SM, Kuzel TM, Yarnold PR et al (2006) Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 106:2051–2057CrossRefPubMed Belknap SM, Kuzel TM, Yarnold PR et al (2006) Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 106:2051–2057CrossRefPubMed
6.
go back to reference Plate JM, Plate AE, Shott S et al (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915–925CrossRefPubMed Plate JM, Plate AE, Shott S et al (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915–925CrossRefPubMed
7.
go back to reference Nowak AK, Robinson BW, Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62:2353–2358PubMed Nowak AK, Robinson BW, Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62:2353–2358PubMed
8.
go back to reference Bracci L, Schiavoni G, Sistigu A et al (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15–25CrossRefPubMed Bracci L, Schiavoni G, Sistigu A et al (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15–25CrossRefPubMed
Metadata
Title
Exacerbation of gemcitabine-related pneumonia during radiotherapy for extrapulmonary lesion
Author
Yukihiro Hama
Publication date
01-01-2017
Publisher
Springer Japan
Published in
International Cancer Conference Journal / Issue 1/2017
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-016-0267-5

Other articles of this Issue 1/2017

International Cancer Conference Journal 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine